Investor’s Business Daily |
AnaptysBio Could Rival Regeneron Pharmaceuticals, Sanofi In …
Investor’s Business Daily AnaptysBio (ANAB) launched to a record high Tuesday after its eczema drug appeared to outperform Regeneron Pharmaceuticals' (REGN) and Sanofi's (SNY) … Here's Why AnaptysBio Inc. Is Rocketing Higher Today AnaptysBio has game-changing results in atopic dermatitis Here's What Just Happened With AnaptysBio, Inc. (NASDAQ:ANAB) |
